ArticleRSC advances2020
Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Composition-tunable polycarboxylic acid-stabilized ultrasmall amorphous paramagnetic nanoclusters as multifunctional MRI contrast agents.Materials today. Bio · 2026Article
- Synthesis of Gd-DOTA-BMTP and its application in gadolinium neutron capture therapy for osteosarcoma.Journal of cancer research and clinical oncology · 2026Article
- Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.Nanomaterials (Basel, Switzerland) · 2025Review
- In vivo dosimetry for proton therapy: A Monte Carlo study of the Gadolinium spectral response throughout the course of treatment.Medical physics · 2025Article
- Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Multifunctional Poly(Acrylic Acid)-Coated EuBiGdInternational journal of nanomedicine · 2025Article
- Biomedical Application Prospects of Gadolinium Oxide Nanoparticles for Regenerative Medicine.Pharmaceutics · 2024Article
- Synthesis of Gd-DTPA Carborane-Containing Compound and Its Immobilization on Iron Oxide Nanoparticles for Potential Application in Neutron Capture Therapy.Pharmaceutics · 2024Article
- Recent progress of nano-drugs in neutron capture therapy.Theranostics · 2024Review
- Gadolinium Neutron Capture Therapy for Cats and Dogs with Spontaneous Tumors Using Gd-DTPA.Veterinary sciences · 2023Article
- Inorganic Nanomaterials Used in Anti-Cancer Therapies:Further Developments.Nanomaterials (Basel, Switzerland) · 2023Review
- In vivo evaluation of the effects of combined boron and gadolinium neutron capture therapy in mouse models.Scientific reports · 2022Article
- Gadolinium Neutron Capture Therapy (GdNCT) Agents from Molecular to Nano: Current Status and Perspectives.ACS omega · 2022Review
- Revisiting the factors influencing the magnetic resonance contrast of GdNanoscale advances · 2021Article
- Functionalized Lanthanide Oxide Nanoparticles for Tumor Targeting, Medical Imaging, and Therapy.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium neutron capture therapy (GdNCT) is considered as a new promising cancer therapeutic technique. Nevertheless, limited GdNCT applications have been reported so far. In this study, surface-modified ultrasmall gadolinium oxide nanoparticles (UGNPs) with cancer-targeting ability (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.